GeNeuro develops a new approach to the treatment of autoimmune diseases, including multiple sclerosis (MS) and Type 1 Diabetes (T1D) associated with pathogenic proteins expressed by human endogenous retroviruses (HERV), viral genes that account for 8% of human DNA.

Products, services, technology

GeNeuro has developed temelimab, a humanized monoclonal antibody targeting pHERV-W Env. Temelimab has proven in the Phase II CHANGE-MS 270-patient trial, and in its ANGEL-MS extension, to have a coherent impact across all key markers associated with disease progression in multiple sclerosis.

Location

Chemin du Pré-Fleuri 3, 1228 Plan-les-Ouates, Switzerland

Facts & figures
  • Type of organization

    Public company

  • Year of foundation

    2006

  • Number of employees in Switzerland

    10-19

Key business